Annotation Detail

Information

Associated Genes: BRAF
Associated Variants: BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 )
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 )
Associated Disease: cholangiocarcinoma
Source Database: CIViC Evidence
Description: Patients with metastatic cholangiocarcinoma havoring with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. Multiple lung metastasis was dramatically regressed and this treatment was continued.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/5906
Gene URL: https://civic.genome.wustl.edu/links/genes/5
Variant URL: https://civic.genome.wustl.edu/links/variants/12
Rating: 3
Evidence Type: Predictive
Disease: Cholangiocarcinoma
Evidence Direction: Supports
Drug: Vemurafenib,Irinotecan,Panitumumab
Evidence Level: C
Clinical Significance: Sensitivity/Response
Pubmed: 26687137

Drugs